(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA), a generic drugs company, on Friday presented positive post-hoc data from the Phase 3 SOLARIS trial for TEV-'749 in treating schizophrenia. The results were presented at the Psych Congress in New Orleans, Louisiana.
Teva Presents Positive Post Hoc Data For TEV-'749 For Schizophrenia; FDA Decision In Q4 '26
(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA), a generic drugs company, on Friday presented positive post-hoc d...
By Dhallo News · September 20, 2026 at 2:44 AM IST
Have feedback on this article?Report error or suggestion
